We are live on
!
Find out more
SVCM
Saturn V Capital Management Portfolio holdings
AUM
$552M
1-Year Est. Return
551.78%
This Fund
S&P 500
This Quarter
Est. Return
+11.61%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$249M
AUM Growth
-$11.8M
(-4.5%)
Cap. Flow
-$27.1M
Cap. Flow
% of AUM
-10.86%
Top 10 Holdings %
Top 10 Hldgs %
71.1%
Holding
28
New
5
Increased
5
Reduced
10
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vaxcyte
PCVX
|
+$12.8M |
| 2 |
Disc Medicine
IRON
|
+$12.3M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
+$11.5M |
| 4 |
FOLD
Amicus Therapeutics
FOLD
|
+$8.93M |
| 5 |
ABVX
Abivax
ABVX
|
+$8.03M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CBAY
Cymabay Therapeutics
CBAY
|
+$17.7M |
| 2 |
Amylyx Pharmaceuticals
AMLX
|
+$16.2M |
| 3 |
Cytokinetics
CYTK
|
+$14.3M |
| 4 |
Biogen
BIIB
|
+$8.4M |
| 5 |
ATXS
Astria Therapeutics
ATXS
|
+$7.61M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Jasper Therapeutics
JSPR
$23.6M
| – | – |
-138,622
| Closed | -$1.09M |
|
|
CBAY
27
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-750,250
| Closed | -$17.7M |
|
|
AMAM
28
DELISTED
Ambrx Biopharma Inc
AMAM
| – | – |
-52,781
| Closed | -$752K |
|
Similar funds
TC
BT
CA
IQI
BCM
TC
LWP
AI
Saturn V Capital Management's Q1 2024 Portfolio in Review
As of Q1 2024, Saturn V Capital Management held 28 positions worth $249M, down 4.5% from $261M the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Saturn V Capital Management withdrew a net $27.1M in Q1 2024, closing 7 positions and reducing 10 holdings. Its most notable exit was Cymabay Therapeutics, an estimated $17.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Saturn V Capital Management opened a new position in Vaxcyte worth $12.6M.
- Saturn V Capital Management's largest Q1 2024 buy was Vaxcyte: 185,175 shares worth $12.6M.
- Saturn V Capital Management added most to Disc Medicine in Q1 2024, an estimated $12.3M increase.
- Saturn V Capital Management's biggest Q1 2024 reduction was Cytokinetics, cutting an estimated $14.3M.
- Saturn V Capital Management fully exited Cymabay Therapeutics in Q1 2024, selling an estimated $17.7M.
- Saturn V Capital Management's ten largest holdings make up 71% of its $249M portfolio in Q1 2024.
- Saturn V Capital Management opened 5 new positions and closed 7 in Q1 2024.
- Saturn V Capital Management's portfolio value fell 4.5% quarter-over-quarter to $249M.
Based on Saturn V Capital Management's 13F filing for Q1 2024, filed 15 May 2024.